• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Mitchell, Claire L
    O'Connor, James P B
    Jackson, A
    Parker, G J M
    Roberts, C
    Watson, Y
    Cheung, S
    Davies, K
    Buonaccorsi, G A
    Clamp, Andrew R
    Hasan, Jurjees
    Byrd, Louise M
    Backen, Alison C
    Dive, Caroline
    Jayson, Gordon C
    Show allShow less
    Affiliation
    Cancer Research UK, Department of Medical Oncology, Christie Hospital and University of Manchester.
    Issue Date
    2010-03-29
    
    Metadata
    Show full item record
    Abstract
    BACKGROUND: Patients with recurrent ovarian cancer often achieve partial response following chemotherapy, resulting in persistent small volume disease. After completion of treatment, the dilemma of when to initiate subsequent chemotherapy arises. Identification of biomarkers that could be used to predict when subsequent treatment is needed would be of significant benefit. Design: Twenty-three patients with advanced ovarian cancer and residual asymptomatic disease following chemotherapy underwent dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) at study entry, 4, 8, 12, 18 and 26 weeks or disease progression. A subgroup of patients provided plasma samples within which a panel of angiogenic biomarkers was quantified. RESULTS: By 4 weeks, significant differences in whole tumour volume, enhancing fraction and Ca125 were observed between patients whose disease progressed by 26 weeks and those who remained stable. Significant correlations between plasma soluble vascular endothelial growth factor recptor-1 (sVEGFR-1) and sVEGFR-2 concentrations, and blood volume and tumour endothelial permeability surface area product measured by DCE-MRI were observed. CONCLUSIONS: Imaging markers have a potential role in early prediction of disease progression in patients with residual ovarian cancer and may supplement current measures of progression. The correlation of DCE-MRI and serological biomarkers suggests that tumour angiogenesis affects these markers through common biological means and warrants further investigation.
    Citation
    Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy. 2010: Ann Oncol
    Journal
    Annals of Oncology
    URI
    http://hdl.handle.net/10541/109400
    DOI
    10.1093/annonc/mdq079
    PubMed ID
    20351070
    Type
    Article
    Language
    en
    ISSN
    1569-8041
    ae974a485f413a2113503eed53cd6c53
    10.1093/annonc/mdq079
    Scopus Count
    Collections
    All Christie Publications
    All Paterson Institute for Cancer Research
    Medical Oncology

    entitlement

    Related articles

    • Prognostic significance of rising serum CA-125 levels within the normal range in patients with epithelial ovarian, primary peritoneal, and tubal cancers, who, after initial treatment, had a complete clinical response.
    • Authors: Levy T, Weiser R, Boaz M, Shem EB, Golan A, Menczer J
    • Issue date: 2012 Oct
    • Low-Grade Serous Carcinoma of the Ovary.
    • Authors: Grisham RN
    • Issue date: 2016 Jul
    • A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.
    • Authors: Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Wouters MC, Kenter GG, van Erkel AR, van Poelgeest MI, Nijman HW, van der Hoeven JJ, Welters MJ, van der Burg SH, Kroep JR
    • Issue date: 2015 Oct
    • Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer.
    • Authors: Mury D, Woelber L, Jung S, Eulenburg C, Choschzick M, Witzel I, Schwarz J, Jaenicke F, Mahner S
    • Issue date: 2011 Jul
    • Chronic administration of single weekly paclitaxel in heavily pretreated ovarian cancer patients.
    • Authors: Yamamoto K, Oogi S, Inoue H, Kudoh K, Kita T, Kikuchi Y
    • Issue date: 2004 Feb
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.